Copper Futures (COPPER): The metal’s rally has been driven in lar...

The metal’s rally has been driven in large

nowwhat2 · 2021-03-27T19:53:15.0900000Z

The metal’s rally has been driven in large part by investors who see demand soaring as the green revolution gathers pace. But their early optimism may end up pushing up costs for governments as they start putting infrastructure spending packages to work. https://www.engineeringnews.co.za/article/green-revolution-gets-more-expensive-as-copper-price-surges-2021-03-04 If copper’s rally proves long-lasting and pushes up the cost of green investment, some wind farms may use cheaper aluminum where they can. Prices have risen less sharply, up 28% in the past year compared with 62% for copper. Demand for aluminum in power grid infrastructure is estimated to reach 7.6-million metric tons by 2050, according to BNEF. LAST Up 10.5 % to 32.78 March 3rd investorshub.advfn.com/uimage/uploads/2021/3/27/kbcfyaa_3_3_hyper_LOGOS_zoom_2_lines_arrow.jpg investorshub.advfn.com/uimage/uploads/2021/3/27/hiynqcopper_3_9_50_y_HYPER.jpg LAST 4.07 https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=&symb=copper&x=45&y=18&time=100&startdate=1%2F1%2F2020&enddate=4%2F4%2F2021&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&style=320&size=3&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=9 investorshub.advfn.com/uimage/uploads/2021/3/27/uenvateck_3_26_ipo_25_zoom_w_copper_futes.jpg

Play Episode

5min

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

Allergy Therapeutics turns the corner, targets market launches

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive's Stephen Gunnion about the company’s financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control. Llobet highlighted that the company saw a 4% constant currency growth in euro-denominated sales—double that of the previous period—driven by improved supply chains and the strong performance of new and registered products. “The top line is good in terms of quantity and quality,” he said. Furlong added that these results, along with the recent financial restructuring, demonstrate a clear path to sustainable health. The company’s cash position rose to £21.7 million at the end of December from £12.9 million in June, aided by external funding and shareholder support. On the clinical side, Llobet described the Grass MATA MPL program as a potential “game changer”, with a Marketing Authorisation Application submitted in Germany. He also noted the progress of the Polyvac Peanut program, which aims to offer a short-course treatment capable of disease modification, differentiating it from current therapies. The company remains focused on progressing these pipeline assets while maintaining financial discipline. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications to stay updated. #AllergyTherapeutics #BiotechNews #Immunotherapy #GrassMATA #PeanutAllergy #VaccineDevelopment #R&D #Pharmaceuticals #FinancialResults #InvestorUpdates #ProactiveInvestors

Proactive - Interviews for investors

Oriole Resources wraps up pivotal 2024, targets major gold milestones in 2025

Oriole Resources PLC (AIM:ORR) CEO Martin Rosser and CFO Bob Smeeton take Proactive's Stephen Gunnion through the company’s latest full-year results and upcoming milestones across its key exploration projects. Rosser highlighted a pivotal year for the company’s Bibemi and Mbe gold projects in Cameroon. At Bibemi, a recently completed phase five drilling campaign is feeding into a revised Mineral Resource Estimate (MRE), expected this quarter. “We believe there's very good potential to not just increase the amount of gold, but also improve the category of the resource,” said Rosser. The company is also advancing an exploitation license application for the project. At Mbe, maiden drilling continues, following trenching results that indicated strong mineralisation. “We think Mbe South has significant potential to host a substantial gold deposit,” Rosser added. Smeeton detailed a £2 million reduction in operating loss and financial support from BCM International. “Since year-end, BCM have given us $1.1 million, largely replenishing CapEx,” Smeeton noted. He also confirmed progress on a joint venture agreement with Managem at the Senala project in Senegal. Rosser pointed to potential sector-wide revaluations driven by high gold prices and possible M&A activity. “Oriole’s shares are significantly undervalued,” he said. For more updates from Oriole Resources and other mining sector interviews, give this video a like, subscribe to Proactive’s YouTube channel, and enable notifications so you don’t miss future content. #OrioleResources #GoldExploration #CameroonMining #MbeProject #BibemiGold #JuniorMiners #MiningInvestment #MineralResourceEstimate #GoldPrice #MiningFinance #ProactiveInvestors #ManagemJV #SenalaProject #CameroonGold #ExplorationDrilling

Proactive - Interviews for investors

Immunic CMO discusses significance of MS Awareness Month; progress with treatment

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s work in multiple sclerosis (MS) as MS Awareness Month concludes. Muehler discussed the importance of continued research funding and the community’s role in advancing treatment. He highlighted the company’s lead asset, vidofludimus calcium, which is in advanced-stage clinical trials. Results from the phase 2 EMPHASIS trial in relapsing-remitting MS showed a reduction of about three-quarters of new MRI lesions compared to placebo. Muehler said, “This is a very good value,” and pointed to biomarker data showing a strong, dose-linear suppression of neurofilament — a sign of nerve cell damage. A phase 3 program involving more than 2,000 patients is now underway, with data expected in 2026. In progressive MS, Immunic is close to reporting data from its phase 2 CALLIPER trial, having already seen positive biomarker signals at 24 weeks. Muehler addressed patients’ fears of disability, stressing the company’s commitment to tackling "progression independent of relapse activity (PIRA)", a key unmet need. He emphasized vidofludimus calcium’s dual mechanism — both anti-inflammatory and neuroprotective — and its potential to become the first oral drug targeting the full spectrum of MS. To hear more insights from Immunic and other biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmunicTherapeutics #MultipleSclerosis #MSAwarenessMonth #vidofludimuscalcium #MSTreatment #ClinicalTrials #Neuroprotection #MSResearch #BiotechNews #ProgressiveMS #RelapsingMS #PIRA #DrugDevelopment

Followers	233
Posts	48666
Boards Moderated	10
Alias Born	02/07/2012

Volume:	-
Day Range:
Bid:	4.4135
Ask:	4.417
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

COPPER Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free